GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma
Retrieved on:
Thursday, February 27, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Medicine, Gut flora, Pathogenic microbes, Yeasts, Branches of biology, Ellipta, Glucocorticoids, Fluticasone furoate, Candida albicans, Cándida, Asthma, the CAPTAIN Study, Trelegy Ellipta (FF/UMEC/VI), GSK, Innoviva
Regulatory applications have also been submitted for the Trelegy duplicate licences, Elebrato Ellipta and Temybric Ellipta.
Key Points:
- Regulatory applications have also been submitted for the Trelegy duplicate licences, Elebrato Ellipta and Temybric Ellipta.
- Trelegy Ellipta is not indicated for relief of acute bronchospasm or for the treatment of asthma.
- The following ISI is based on the Highlights section of the US Prescribing Information for Trelegy Ellipta.
- Candida albicans infection of the mouth and pharynx has occurred in patients treated with fluticasone furoate, a component of Trelegy Ellipta.